Collegium (COLL) Xtampza ER Sales More than Double Expectations - William Blair
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Collegium Reports Third Quarter Financial Results and Provides Corporate Update
November 8, 2017 4:01 PM ESTXtampza® ER prescriptions grow by 49% in the third quarterFDA Approval of sNDA, including Comparative OxyContin DataStrong balance sheet provides cash runway into mid-2019 Conference call scheduled for today at 4:30 p.m. ET
CANTON, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the third quarter of 2017 and provided a corporate update.Â
We are encouraged by the continued adoption of Xtampza ER with consistent prescription growth during the third quarter, said Michael... More
